Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Cantwinemallon Jun 08, 2018 3:47pm

76 Views

Post# 28147791

RE:RE:Charts

naa man, charts always paint a picture. RSI extremely over sold. Bids are lite to 15 cents. Could rebound nicely.

ArticBlubber wrote: Charts , technical numbers do not apply for Kalytera :) .. bills/warrants/emotions driven stock :). Few weeks ago some people predicted we shall have a green run etc, but we dropped down further :) But yes, honestly I would love to see it trading higher. Hope

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports